Overview of Yanimo

Property	Description
Active ingredients	Olodaterol, Tiotropium Bromide
Form	Inhalation solution (specifically designed device)
Pharmacological Class	Combination Bronchodilator (LABA/LAMA)
General Purpose	Long-term maintenance treatment
Rx Status	Prescription-only medicine

What Type of Medicine is Yanimo?

Yanimo is an advanced, Fixed-Dose Combination (FDC) bronchodilator prescribed exclusively as a prescription-only medicine for the maintenance treatment of chronic airflow limitation. This medication is classified as an anti-obstructive respiratory agent that unites two distinct components to ensure maximal widening of the air passages. Yanimo delivers concurrent action from both a Long-Acting Beta-Agonist (LABA), which is Olodaterol, and a Long-Acting Muscarinic Antagonist (LAMA), which is Tiotropium Bromide. This dual approach is a clinically recognized standard for providing comprehensive, sustained respiratory support.

Composition and Drug Form

The active ingredients in Yanimo are Olodaterol (as hydrochloride) and Tiotropium (as bromide), prepared as a specialized inhalation solution according to pharmaceutical standards. This combination is specifically formulated for delivery via a compact metered-dose device, ensuring the product's unique formulation is effectively delivered directly to the airways. The active compounds are suspended in an aqueous solution, a deliberate choice of base to facilitate the co-delivery of both active agents.

General Purpose and Benefit

The overall general purpose of Yanimo is to provide a sustained action to help adult patients breathe more easily by maintaining airway patency for a full 24-hour period. Olodaterol relaxes the smooth muscles around the airways, while Tiotropium Bromide actively prevents these muscles from contracting. This combined, synergistic effect effectively alleviates the persistent airflow limitation seen in Chronic Obstructive Pulmonary Disease (COPD). Fixed-Dose Combination products combining LABA and LAMA agents offer superior bronchodilation compared to either monotherapy. This consistent effect is clinically supported to promote stability in respiratory function and is crucial for patients managing their chronic condition.

Regulatory References

Tiotropium and olodaterol (inhalation route)

What side effects are possible with Yanimo?

Possible Side Effects and Safety Information

The safety profile of Yanimo (Olodaterol/Tiotropium Fixed-Dose Combination) is based on official government regulatory documents, detailing adverse reactions by frequency and organ system. This information is critical for understanding the drug's risk profile.

Common Adverse Reactions

The most Common side effects, occurring in one percent or more of patients during clinical studies, include nasopharyngitis, upper respiratory tract infection, cough, dizziness, rash, diarrhea, back pain, and arthralgia (joint pain). Less common, or Uncommon, reactions include dry mouth, palpitations, and blurred vision.

Serious and Clinically Significant Risks

Official regulatory labeling highlights several serious risks that require immediate attention:

Paradoxical Bronchospasm: A severe, life-threatening reaction involving unexpected tightening of the airways immediately after administration; requires prompt discontinuation.
Immediate Hypersensitivity Reactions: Acute allergic reactions such as angioedema (swelling of the face, lips, or tongue) or anaphylaxis.
Cardiovascular Effects: Potential for clinically significant changes including QTc prolongation, increased pulse rate, and elevated blood pressure.
Worsening of Pre-existing Conditions: Caution is necessary in patients with existing narrow-angle glaucoma or urinary retention as symptoms may worsen.

Safety Restrictions and Special Populations

Yanimo is contraindicated for use in patients with a history of hypersensitivity to its active components (Olodaterol, Tiotropium) or the related compound ipratropium. It must not be used in combination with any other long-acting beta2-adrenergic agonists (LABAs). Special caution is advised for patients with moderate-to-severe renal impairment and those with severe cardiovascular disorders. The medicine is intended only for maintenance treatment and is not indicated for the relief of sudden, acute breathing symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this fixed-dose combination bronchodilator is primarily associated with the exaggerated pharmacological effects of its components. Immediate medical attention must be sought if an overdose is suspected, as documented severe manifestations may be life-threatening.

Overdosage with the Olodaterol component (LABA) results from excessive beta-adrenergic stimulation. Documented clinical manifestations include severe tachycardia, cardiac arrhythmias, myocardial ischemia, hypertension or hypotension, tremor, and nervousness. A severe overdose may lead to metabolic acidosis, cardiac arrest, and death.

Overdosage with the Tiotropium component (LAMA) may result in exaggerated anticholinergic signs such as dry mouth and dry eyes.

Emergency Actions and Management

Contact emergency services immediately if symptoms such as significant palpitations, chest pain, or severe systemic effects are observed. Regulatory labeling states that there is no specific antidote known for the combination product.

Management is strictly symptomatic and supportive, requiring the discontinuation of the medication. Patients require hospital monitoring, which must include continuous electrocardiographic monitoring and the assessment of electrolyte status due to the potential for hypokalemia.

Therapeutic Uses of Yanimo

What Yanimo Treats: Main Uses and Benefits

Yanimo (Olodaterol/Tiotropium FDC) is generally used as a long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adult patients. This therapy addresses chronic airflow limitation, which is characteristic of conditions like chronic bronchitis and emphysema. It is not intended for the relief of sudden, acute symptoms or breathing crises. The medication is applied across therapeutic domains where additional symptomatic support is needed.

Key Therapeutic Focus

Yanimo is commonly used in conditions characterized by periods of heightened symptoms and is relevant when symptoms produce significant symptomatic burden. The therapy is relevant for easing symptoms related to persistent respiratory distress, including chronic shortness of breath (dyspnea), recurrent chest tightness, and chronic wheezing. This combination therapy assists with managing these symptoms, contributing to easing the overall symptom load.

Benefits and Clinical Context

This medication is generally applied in clinical contexts where additional symptomatic support is needed, assisting with maintaining functional stability. The support provided for chronic airflow limitation may assist with practical benefits, such as improved exercise capacity and easier management of daily activities. Yanimo is commonly used when symptoms intensify, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Persistent Breathlessness

This therapy is relevant for easing symptoms that interfere with daily comfort, supporting patients during difficult symptomatic episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Yanimo?

The official eligibility profile for Yanimo (Olodaterol/Tiotropium FDC) is defined by strict regulatory criteria based on age, disease status, and existing conditions. The medication is only indicated for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adult patients (18 years and older). The standard adult dose is also applicable to geriatric patients.

Contraindicated Populations

Yanimo is strictly contraindicated in specific populations:

Individuals with a known hypersensitivity to tiotropium, olodaterol, or any excipient in the product.
Patients with asthma who are not using a long-term asthma control medicine.
It must not be used to treat acute COPD exacerbations or acute bronchospasm.

Restrictions and Limitations

Use is not recommended in the pediatric population (under 18 years of age) because safety and effectiveness have not been established. Patients with moderate to severe renal impairment require close monitoring. Caution is also advised for individuals with narrow-angle glaucoma, prostatic hyperplasia, or certain cardiovascular disorders. Use is generally not recommended during pregnancy or lactation unless the benefits outweigh the risks; similarly, use is not established for patients with severe hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Yanimo (Olodaterol/Tiotropium) has documented interaction patterns primarily related to the combined effects of its Long-Acting Beta Agonist (LABA) and Long-Acting Muscarinic Antagonist (LAMA) components, as specified in government regulatory documents.

Official Restrictions and Avoidance

Regulatory labels establish strict constraints for co-administration due to the potential for pharmacodynamic reinforcement:

Other Long-Acting Beta Agonists (LABA) are formally prohibited due to the risk of additive cardiovascular effects.
Other Anticholinergic Medications must be avoided because of the potential for additive systemic anticholinergic effects.

Documented Pharmacodynamic Effects

Co-administration with the following drug classes requires official caution as they may potentiate known drug effects:

MAO Inhibitors, Tricyclic Antidepressants, and QTc-Prolonging Drugs may potentiate the effect on the cardiovascular system.
Xanthine Derivatives, Steroids, or Non-Potassium Sparing Diuretics may potentiate the risk of hypokalemia or ECG changes.
Beta-Blockers may decrease effectiveness of the Olodaterol component and should generally be avoided.

Pharmacokinetic and Population-Specific Notes

A pharmacokinetic interaction is documented with Ketoconazole (a P-gp and CYP inhibitor), which increases the systemic exposure of Olodaterol by approximately 70%; regulatory labels state no dose adjustment is necessary. Furthermore, in patients with moderate to severe renal impairment (Creatinine Clearance le 50 mL/min), the plasma concentration of Tiotropium is officially increased due to reduced clearance, necessitating monitoring for systemic anticholinergic effects. The label does not include mandatory timing separation rules or clinically significant food or alcohol interactions.

Mechanism of Action

How Yanimo Works

Yanimo influences the two main neuroregulatory control systems of the airways to produce a prolonged bronchodilatory effect.

Targeting Dual Autonomic Pathways (beta2 and M3)

The mechanism addresses both the beta2-adrenergic (sympathetic) and M3 muscarinic (parasympathetic) receptor systems, modulating both primary neural pathways influencing airway smooth muscle tone. The beta2-agonist component (Olodaterol) initiates a relaxation cascade, while the M3 antagonist component (Tiotropium) establishes a protective blockade against the primary constrictor signal, acetylcholine.

Synergistic cAMP Cascade and Gq Pathway Blockade

The dual action is pharmacologically complementary: Olodaterol actively relaxes the muscle by increasing the second messenger cyclic AMP (cAMP), while Tiotropium prevents contraction by inhibiting the M3 receptor's Gq-protein pathway. This synergistic engagement results in the pronounced widening of the air passages, which physiologically produces a reduction in airway resistance and decreases pulmonary hyperinflation (air trapping).

Sustained Receptor Dissociation Kinetics

The drug's extended duration of action is dictated by specific receptor kinetics. Both Olodaterol and Tiotropium exhibit slow dissociation from their respective targets (beta2-AR and M3), providing a stable and continuous presence on the smooth muscle cell membrane. This mechanism supports the prolonged physiological stability of the airway caliber over a 24-hour period.

Dosage and Administration Information

How to Use Yanimo: Official Administration Guidelines

Yanimo (Olodaterol/Tiotropium FDC) is structured around a precise, fixed regimen. The medication is an inhalation solution that must be administered solely via oral inhalation using the specific soft mist inhaler device provided. This medicine is designed strictly for long-term maintenance treatment of chronic airflow limitation and is not to be used for the relief of sudden, acute breathing symptoms.

Labeled Dosing and Schedule

The standard adult dose for maintenance therapy is two inhalations (puffs) taken once daily. This constitutes the full prescribed dose of 5 mcg tiotropium and 5 mcg olodaterol. It is essential to maintain a consistent schedule by administering the dose at the same time each day. It is important to note that the total daily dose must not exceed two inhalations in a 24-hour period.

Procedural Principles and Populations

Before the first use, the specialized device requires priming, and it must be re-primed if it has not been used for a specified number of days. If a dose is missed, it should be taken as soon as remembered; however, patients must not take two doses within close proximity to compensate for the missed one. No dose adjustment is required for older adults (geriatric patients), nor is an adjustment specified for patients with mild-to-moderate hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Yanimo

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

The evidence base for Yanimo (Olodaterol/Tiotropium combination) comes primarily from randomized controlled trials (RCTs), which are recognized as a high standard of clinical research. These replicate, randomized, controlled trials were designed to evaluate the fixed-dose combination (FDC) for the long-term maintenance treatment of COPD in adult patients. Researchers examined how the combination compared to taking an inactive treatment (placebo) and how it compared to taking each of the two active components (Olodaterol or Tiotropium) by themselves.

The populations studied included adult patients with confirmed COPD, typically those classified as having moderate to very severe disease. Across these studies, findings describe patterns observed in the studies regarding measured lung capacity and reported breathing symptoms when the combination was evaluated in these patient groups.

Measurement of Lung Function and Breathing

To understand how the medicine was studied for its intended purpose, researchers measured objective lung function using tools like the Forced Expiratory Volume in 1 second (FEV1). This outcome measure is relevant in evidence describing how symptoms are measured and captures how much air a person can exhale in a specific time. The trials also monitored patient-reported outcomes, such as the measurement of rescue medication use. Research describes how the combination was observed in trials that focused on breathing capacity.

Evaluation of Symptoms and Health Status

Other studies applied questionnaires and scales to explore outcomes related to physical discomfort and daily functioning or activity level. For example, the Transition Dyspnea Index (TDI) was used in research exploring how symptoms change over time, specifically measuring shortness of breath (dyspnea). Additionally, the St. George’s Respiratory Questionnaire (SGRQ) was applied in studies examining patient-reported experiences of health and quality of life. The findings help contextualize how patients reported their experience of their condition while using the medicine under controlled research conditions.

Long-Term Studies and Follow-Up Duration

A crucial part of the evidence for Yanimo includes studies with long-term follow-up durations, with the primary trials tracking patients for up to 52 weeks (one full year). This extended observation period was used in observational settings evaluating daily-life functioning and allowed researchers to monitor patient responses over defined time intervals. While these trials provide substantial data for a year, there is limited information for long-term outcomes beyond the initial 52-week period.

What is Still Uncertain About the Research Evidence

The available evidence landscape, while extensive in areas of lung function and symptoms, still contains some research limitations. The core trials were not specifically designed or powered to provide dedicated comparative evidence regarding differences in COPD exacerbation frequency between the FDC and its monocomponents.

Furthermore, there is a recognized limitation in the published literature concerning comparative evidence that directly measures the performance of Yanimo against all other similar fixed-dose LAMA/LABA combinations currently available. The research did not include studies of the medicine’s evaluation in asthma or when managing acute, sudden episodes of breathing difficulty.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Yanimo (FAQ)

Q: What is the typical time frame for noticing the effect of Yanimo?

Yanimo is intended for long-term maintenance treatment and is not used for immediate relief of sudden breathing problems. While bronchodilation is observed following administration, the medicine supports sustained bronchodilation over a full 24-hour period with consistent, daily use.

Q: How is Yanimo different from [similar drug name/category]?

Yanimo is officially described as a Fixed-Dose Combination (FDC) medicine. It unites a Long-Acting Beta-Agonist (LABA) and a Long-Acting Muscarinic Antagonist (LAMA) to achieve two distinct actions for COPD maintenance. Official research evidence was primarily focused on comparing this combination to its individual components and a placebo.

Q: Can Yanimo be used for purposes other than what my doctor prescribed?

Yanimo is approved and indicated only for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults. Official documents state it is not approved for the treatment of asthma or acute COPD exacerbations (sudden, severe breathing problems).

Q: What does 'contraindicated' mean in relation to Yanimo's use?

The term contraindicated means the medicine should never be used by people with specific conditions, such as a known allergy to its active ingredients or for treating asthma. Official documents state this is because the potential risks significantly outweigh any possible benefits in these situations.

Q: Is Yanimo known to cause dependence or addiction?

Yanimo (olodaterol/tiotropium) is not classified as a controlled substance by the U.S. Drug Enforcement Administration ( DEA) or under the Controlled Substances Act ( CSA). The medicine is not an opioid and is not associated with dependence.

Q: Is there a generic version of Yanimo available?

According to regulatory status information, a generic version of the fixed-dose combination (olodaterol/tiotropium) is not currently available. Yanimo is only available as the brand-name product.

Q: Is Yanimo safe for people who drive or operate heavy machinery?

Official product information states that Yanimo can cause side effects such as dizziness, blurred vision, or tremors. Official warnings describe avoiding activities requiring mental alertness, such as driving or operating heavy machinery, until the patient understands the medicine's effects.

Q: What happens if a patient stops taking Yanimo suddenly?

Yanimo is indicated as a long-term maintenance therapy for a chronic condition. Regulatory information indicates that because the drug is for chronic use, sudden cessation is associated with a risk of worsening COPD symptoms.

Q: Does Yanimo have a maximum approved duration of use?

The indication for Yanimo is for long-term maintenance treatment of COPD. There is no specified maximum duration, as treatment is intended for chronic management. Clinical trials reviewed the safety profile for up to 52 weeks.

Q: What is the purpose of the 'Black Box Warning' (if applicable) for Yanimo?

As a product containing a LABA component, Yanimo carries a class warning regarding the increased risk of asthma-related death associated with LABAs. Official information strictly states that Yanimo is contraindicated and not approved for treating asthma.

Q: What if I take Yanimo with common vitamins or supplements?

Formal interaction studies with common vitamins or general supplements are typically not reported in regulatory documents. However, official information does caution about using substances like Xanthine derivatives, which may increase the risk of side effects like low potassium levels ( hypokalemia). The information is limited to these specific drug classes.

Q: Does Yanimo interact with any commonly used over-the-counter pain relievers?

Regulatory documents focus on warnings related to prescription medicines like Beta-Blockers and certain antidepressant classes. Official documentation does not provide specific information on most common non-prescription pain relievers.

Q: Can a patient drink coffee while taking Yanimo?

Official regulatory information does not contain a mandatory caution against the consumption of coffee. However, caution is advised when using Xanthine derivatives (pharmacologically similar to caffeine) because of the potential for increased cardiovascular effects or low potassium levels.

Q: Can Yanimo change the results of blood tests?

Official warnings indicate that the LABA component of Yanimo can cause temporary changes in blood chemistry. This can include a decrease in serum potassium and an increase in plasma glucose (blood sugar), which are markers checked in blood tests.

Q: Does Yanimo affect sleep patterns or energy levels?

Official safety documents list trouble sleeping ( insomnia) as a common reported side effect in clinical trials, occurring in 1% or more of patients. This information indicates a potential for the medicine to affect sleep patterns.

Q: What does the term 'long-term safety profile' mean for Yanimo?

The term long-term safety profile refers to the overall safety data collected from clinical trials that followed patients for an extended duration. For Yanimo, this observation period typically covered up to 52 weeks (one year) to monitor side effects over time.

Q: What should a person do if they suspect an allergic reaction to Yanimo?

The official product label states that if immediate hypersensitivity reactions (like swelling of the face or throat, or a rash) or paradoxical bronchospasm (sudden difficulty breathing) occur, the medicine should be discontinued immediately. Official labeling describes the required action is immediate discontinuation of the medicine.

How should Yanimo be stored and disposed of?

Official Storage and Handling Requirements

Yanimo (tiotropium/olodaterol inhalation solution) must be stored strictly according to the official product label to ensure efficacy and integrity.

Requirement	Official Labeled Statement
Temperature	Store in a closed container at room temperature.
Protection	Keep the medicine away from heat, moisture, and direct light.
Prohibited	Keep from freezing (Do not freeze).
Child Safety	Keep out of the sight and reach of children

Stability and Disposal

To maintain the labeled dose, the inhaler must be thrown away 3 months after its first use or when the dose counter locks, whichever occurs sooner.

Regulatory documents mandate that unused or expired medicine should not be thrown away via wastewater or household waste. Patients should consult their healthcare professional or pharmacist regarding the proper disposal of the inhaler through authorized collection schemes, which is the preferred method for pharmaceutical waste.

Yanimo